Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide versus high-dose dexamethasone in relapsed refractory multiple myeloma
2005-004937-16Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Time to progression and Median time to progression and toxicity for dose selection. Started Dec 2005; status: completed.
02
Drugs
thalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-004937-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004937-16.